Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 9Sarcoma 2

Conditions

Osteosarcoma 2Neuroblastoma 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × dinutuximab × Sarcoma × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT02484443 2023-10-26

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 15 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡